Clinical Trial Update: TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase II trial of TGRX-326 for advanced non-small cell lung cancer in China is currently active but not recruiting. The study is sponsored by Shenzhen TargetR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TGRX-326

Snippet

Sponsor: Shenzhen TargetRx Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING